Salute e Benessere

Fermion announces IND Approval of Non-Addictive Pain Relief Drug FZ008-145 by…

In October 2023, Fermion signed an agreement with Joincare Pharmaceutical Group Industry Co., Ltd., granting exclusive rights for the company's independently developed pain medication FZ008-145 in the Greater China region, while retaining rights outside of Greater China. InOctober 2023, Fermion signed an agreement with Joincare Pharmaceutical Group Industry Co., Ltd., granting exclusive rights for the company's independently developed pain medication FZ008-145 in theGreater Chinaregion,...
PR Newswire
10/01/2024

Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot…

Saint-Herblain (France), January 10, 2024–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA) today announced that the first participant has been vaccinated in the Phase 2 clinical trial evaluating the safety and Immunogenicity in children of two different dose levels of Valneva's single-shot chikungunya vaccine. The Company reported positive pivotal Phase 3 data in adolescents two months ago confirming the immunogenicity and safety profile observed in adults 1. There is currently no...
Nasdaq GlobeNewswire
10/01/2024

Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for…

Ad hoc announcement pursuant to Art. 53 LR CEO, Jean-Paul Clozel, to update on how Idorsia is being adapted for sustainable value creationThe company is focused on extending the cash runway beyond the current estimate of early April 2024, through various avenues, including potential out-licensing dealsPostponement of the publication of Full-Year 2023 Financial Results and the subsequent Annual General Meeting of ShareholdersAllschwil, Switzerland – January 10, 2024Idorsia Ltd (SIX:...
Nasdaq GlobeNewswire
10/01/2024

BioSenic appoints Dr Carole Nicco as Chief Operating Officer in addition to…

PRESS RELEASE Dr Nicco's new Chief Operating Officer (COO) position will give her a broader mandate at BioSenic, where she is currently responsible for R&D programs. Mont-Saint-Guibert, Belgium, January 10, 2024, 7.00 am CEST –BIOSENIC(Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, today announces the promotion of Dr Carole Nicco to Chief...
Nasdaq GlobeNewswire
10/01/2024

Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a…

TORCHLIGHT is the first registered Phase 3 study to achieve positive results in advanced TNBC immunotherapy in China. It was jointly conducted across 56 centers nationwide, with principal investigator Professor Zefei JIANG from the Department of Oncology of the Chinese People's Liberation Army General Hospital and Vice President and Secretary General of the Chinese Society of Clinical Oncology (CSCO).“Using immunotherapy with Chinese products and designs to address the challenges of...
Nasdaq GlobeNewswire
10/01/2024

Novogene Bolsters Global Presence with Expanded PacBio Revio Fleet, Advancing…

"We stand as a global leader among sequencing service providers, distinguished by our diverse range of platforms, extensive production capacity, and deep R&D expertise. Our commitment is to be a cornerstone in the life sciences industry, offering solutions that are not only accurate and rapidly delivered but also of superior quality and cost-effective," said Li Yixue, GM of Novogene Global Product Center. "We stand as a global leader among sequencing service providers…
PR Newswire
10/01/2024

Eureka Ushers in a New Era of Home Cleaning Innovation at CES 2024

Eureka: A Century-Old Brand Embracing the Future Eureka: A Century-Old Brand Embracing the Future Since its inception in 1909, Eureka has been synonymous with innovation and quality in home cleaning. This year, the brand introduced its new tagline, "Life, there's a Eureka for that" capturing the essence of its mission to provide comprehensive cleaning solutions for every home and lifestyle. Eureka's product range, from cordless and upright vacuums to portable carpet cleaners and…
PR Newswire
09/01/2024

Cold Chain Market worth $733.7 million by 2030, at a CAGR of 15.3 %, says…

Key Market Takeaways: Key Market Takeaways: The cold chain packaging market is anticipated to witness a CAGR of 15.3% during the forecast period 2023-2030, owing to the increasing demand for temperature-sensitive products and the need for effective cold chain management. On the basis of type, the storage components segment is expected to hold a dominant position, owing to the critical role it plays in maintaining food and drug quality. The transportation and monitoring components...
PR Newswire
09/01/2024

Achondroplasia Treatment Drug Market to Register Positive Growth by 2032…

Key Takeaways from the Achondroplasia Market Report Key Takeaways from the Achondroplasia Market Report Discover which therapies are expected to grab the major achondroplasia market share @Achondroplasia Market Report Achondroplasia Overview Achondroplasia, a rare genetic disorder affecting bone growth, causes significant short stature due to a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. This mutation results in an overactive FGFR3 gene, slowing bone...
PR Newswire
09/01/2024

Fortrea Establishes Industry Partnership with Veeva and Advarra to Streamline…

Companies partner to provide patients and sites with easy access to study information in one integrated solution Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced an industry partnership with founding members Veeva Systems Inc., a leading provider of industry cloud solutions for the global life sciences industry, and Advarra, a leading provider of clinical research technology for clinical research investigator sites and...
Nasdaq GlobeNewswire
09/01/2024

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023Mont-Saint-Guibert, Belgium – January 9, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2023. ...
Nasdaq GlobeNewswire
09/01/2024

Lifespan Vision Ventures invests in Bolden Therapeutics

"We are extremely excited to have Lifespan Vision Ventures as part of Team Bolden," said Johnny Page, co-founder and CEO of Bolden Therapeutics, Inc. "The next several months are a crucial time for the company and Lifespan's partnership represents a fantastic step towards achieving our goal of developing therapies to combat neurological diseases." "We are extremely excited to have Lifespan Vision Ventures as part of Team Bolden," said Johnny Page, co-founder and CEO…
PR Newswire
09/01/2024

IBA - Regulated Information

IBA – TRANSPARENCY NOTIFICATION(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)Louvain-la-Neuve, Belgium, January 9 th, 2024, 18:00 Summary of the notificationIBA (Ion Beam Applications), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major...
Nasdaq GlobeNewswire
09/01/2024

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 9 January 2024— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk...
Nasdaq GlobeNewswire
09/01/2024

Neurolief's Relivion® Secures Regulatory Approval in Japan, Pioneering At-Home…

Marketing efforts for Relivion® will be led by Sawai Pharmaceutical Co., Ltd, which have entered into an exclusive partnership agreement with Neurolief for development and commercialization of Relivion® for migraine and depression indications in Japan. Marketing efforts for Relivion ®will be led by Sawai Pharmaceutical Co., Ltd, which have entered into an exclusive partnership agreement with Neurolief for development and commercialization of Relivion ®for migraine and depression indications...
PR Newswire
09/01/2024

Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for…

"At Menarini, we believe that the addition of cefepime-taniborbactam expands our existing AMR anti infectives portfolio and provides the opportunity to further strengthen our building of an important antibiotics portfolio focused on the critical pathogens responsible for the vast majority of antibiotic resistance" said Elcin Barker Ergun, CEO of the Menarini Group. "By leveraging our expertise and Menarini's expansive commercial infrastructure, we will provide the resources needed…
PR Newswire
09/01/2024

Liquid Filled Capsules Market to Reach $ 2,113.9 Million by 2034, Driven by Drug…

Request Exclusive Sample Report: Liquid Filled Capsule Industry Strategic Insights https://www.futuremarketinsights.com/reports/sample/rep-gb-18786 Request Exclusive Sample Report: Liquid Filled Capsule Industry Strategic Insightshttps://www.futuremarketinsights.com/reports/sample/rep-gb-18786 The market for liquid-filled capsules is expanding rapidly, which indicates a changing environment influenced by several variables. One key factor driving this trend is the growing need from...
PR Newswire
09/01/2024

Ayurvedic Herbal Extract Market to Reach $68.6 Billion Globally by 2032 at 5.2%…

Request Sample Report: https://www.alliedmarketresearch.com/request-sample/244379 Request Sample Report:https://www.alliedmarketresearch.com/request-sample/244379 Prime Determinants of Growth The rising preference for natural products with less minimal side effects in the cosmetic and medical sectors and the growing awareness regarding the adverse effects associated with synthetic therapies are the factors expected to drive the growth of the global ayurvedic herbal extract...
PR Newswire
09/01/2024

Therapeutic Vaccines Market Size and Share to Surpass USD 87 Billion by 2035 -…

LONDON, Jan. 9, 2024 /PRNewswire/ -- The global therapeutic vaccines market is estimated to be worth USD 2 billion in 2023 and is anticipated to reach USD 87 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 35% during the forecast period from 2023 to 2035. LONDON,Jan. 9, 2024/PRNewswire/ -- The global therapeutic vaccines market is estimated to be worthUSD 2 billionin 2023 and is anticipated to reachUSD 87 billionby 2035. It is expected to...
PR Newswire
09/01/2024

Crossject to present at Biotech Showcase on January 9 at 16:30 PT

Press ReleaseCrossject to present at Biotech Showcase on January 9 at 16:30 PT Dijon, France, January 9, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations,will hold a presentation at the Biotech Showcase conference, being held in San Francisco, on January 9, 2024 at 16:30 PT (January 10, 01:30 CET).Details of the presentation:Time: Tuesday, January 9, 2024, 16:30 PTTrack:...
Nasdaq GlobeNewswire
09/01/2024

Infectious Disease Diagnostics Market Worth $31.5 Billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589 Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589 Browse in-depth TOC on "Infectious Disease Diagnostics Market" 172 - Tables 53 - Figures 309 - Pages Infectious Disease Diagnostics Market Scope: In 2022, the reagents, kits, and consumables segment held the largest share of the infectious disease diagnostics market...
PR Newswire
09/01/2024

Walking Assist Devices Market to Reach $6.6 Billion, by 2032 at 6.3% CAGR…

Request Sample of the Report on Walking Assist Devices Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/7884 Request Sample of the Report on Walking Assist Devices Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/7884 Prime determinants of growth The walking assist devices market has experienced significant growth rise in geriatric population and high adoption of walking assist devices for rehabilitation after surgeries and...
PR Newswire
09/01/2024

Exoskeleton Market Size to Exceed to USD 20.3 Billion By 2035 Says, Roots…

Global Exoskeleton Market Overview Global Exoskeleton Market Overview The globalexoskeleton marketis estimated to be worthUSD 1.67 billionin 2023 and is anticipated to reachUSD 20.3 billionby 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 23.1% during the forecast period (2023-2035). A medical exoskeleton is a form of wearable electromechanical equipment specifically designed to improve mobility in patients suffering from neurological disorders...
PR Newswire
09/01/2024

Health Recovery Solutions (HRS) Applauded by Frost & Sullivan for Transforming…

HRS's Logistics and Inventory (asset) Management handles hardware-related needs, from procurement to distribution and maintenance. The company assumes responsibility for administrative tasks such as equipment delivery, in-home installation and onboarding via HRS' HomeDirect program, remote-led patient onboarding, returns coordination, and kit servicing, allowing organizations to seamlessly scale their operations, expedite enrollment, and maintain high-quality control. Clinical and non-clinical…
PR Newswire
09/01/2024
Altri  Comunicati